+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of AZD6234 in adults who have obesity or are overweight with at least one weight-related health condition but do not have type 2 diabetes. This Phase III study is randomized, double-blind, and conducted across multiple centers worldwide. Participants will be assigned to receive either AZD6234 or a placebo to compare changes in body weight over 68 weeks of treatment. The study treatments involve subcutaneous injections once a week. Participants will receive one of two doses of AZD6234 or a matching placebo. The trial aims to assess how these treatments affect body weight, waist circumference, triglycerides, blood pressure, and fat mass, including measurements by DXA scans in a subset of participants. The treatment period lasts 68 weeks. During the study, participants will have regular visits for assessments including body weight, waist circumference, blood pressure, and blood tests. Some will have DXA scans to measure fat mass. Researchers will monitor safety and track the percentage change in body weight from the start of treatment. The total participation duration includes 68 weeks of treatment with monitoring at specified intervals.

Age: 18Years +All GendersPhase 3
220 locations
E

Actively Recruiting

The trial investigates how well AZD6234 works and its safety in adults who have Type 2 Diabetes Mellitus along with obesity or excess weight. This Phase III, global, randomized, double-blind study compares AZD6234 to a placebo to measure changes in body weight over 68 weeks of treatment. The study aims to better understand weight loss effects and related health changes in this population. Participants will be randomly assigned to one of three groups two different doses of AZD6234 or a placebo. The treatments are given by weekly subcutaneous injections. The study will last 68 weeks, during which participants receive their assigned injections and are monitored regularly for effectiveness and safety. Throughout the study, participants will attend multiple visits for evaluations, including body weight, waist circumference, blood pressure, and lab tests such as haemoglobin A1C and triglycerides. Some may undergo DXA scans to measure fat mass. Researchers will track changes from baseline to assess weight loss and metabolic effects. Safety and tolerability will also be monitored over the treatment period, which lasts about 68 weeks.

Age: 18Years +All GendersPhase 3
230 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a half-dose bolus of recombinant staphylokinase r-SAK given before primary percutaneous coronary intervention PCI in patients with acute ST-segment elevation myocardial infarction STEMI. This phase 4, multi-center, randomized, double-blind, placebo-controlled trial aims to determine whether adding r-SAK immediately before PCI improves outcomes compared to placebo within 120 minutes of the procedure. The study is motivated by the need to improve early reperfusion and reduce heart damage in STEMI patients. Participants are randomly assigned to receive either a single intravenous bolus of 5 mg r-SAK over 3 minutes or a placebo injection within 10 minutes after STEMI diagnosis and before PCI. The trial compares these two groups to assess the impact on major adverse cardiovascular events MACE within 90 days. The study also monitors other heart and brain event outcomes, heart function measures, and blood flow grades before and after PCI. During the study, participants undergo assessments including cardiac magnetic resonance imaging, echocardiograms, and blood tests for heart-related biomarkers at specified days up to 360 days after treatment. Researchers observe the occurrence of cardiovascular events, measure heart function, and monitor safety outcomes throughout the trial period. Participants are followed to evaluate both short-term and longer-term effects of the treatment compared to placebo.

Age: 18Years - 75YearsAll GendersPhase 4
61 locations
P

Actively Recruiting

Researchers are evaluating HS-20093, a humanized IgG1 antibody-drug conjugate that targets B7-H3, which is commonly found on solid tumor cells. This open-label, multi-center phase 2 study focuses on Chinese adults with recurrent, locally advanced, or metastatic esophageal carcinoma and other advanced solid tumors. The study aims to assess the anti-tumor activity, safety, pharmacokinetics, and immune response of HS-20093. The study is divided into two parts phase IIa and phase IIb. In phase IIa, participants with relapsed, locally advanced, or metastatic esophageal carcinoma and other solid tumors will receive intravenous doses of HS-20093 every three weeks. Phase IIb will enroll participants specifically with relapsed, locally advanced, or metastatic esophageal squamous cell carcinoma, also receiving HS-20093 by intravenous infusion every three weeks. Treatment continues until unacceptable side effects occur or the disease progresses. Participants will undergo regular evaluations including tumor assessments according to RECIST 1.1 criteria to measure response rate, duration of response, disease control, progression-free survival, and overall survival up to 24 months. Safety is monitored through adverse event tracking up to 90 days after the last dose. Blood samples will be collected to analyze drug levels and immune reactions. The study duration includes treatment and follow-up to monitor these outcomes and overall participant health.

Age: 18Years +All GendersPhase 2
21 locations